Helus Pharma, the commercial operating name of Cybin Inc., reported four poster presentations on investigational HLP003 at Psych Congress 2026 and said Chief Executive Officer Michael Halstead will participate in a TD Cowen neuropsychiatry summit fireside chat on Sept. 23, 2026. Three posters expanded on findings from a completed Phase 1/2a randomized, double-blind study, including 12-month efficacy results, while a fourth outlined the ongoing Phase 3 PARADIGM program for HLP003 as an adjunctive treatment for major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, while HLP004 is in Phase 2 development for generalized anxiety disorder. The newer announcement confirms the summit, identifies Helus Pharma under ticker HELP and provides no additional participation details. Helus Pharma said its products remain investigational, regulatory authorities have not evaluated related claims, and efficacy has not been confirmed by approved research.